The authors speculated that a therapeutic strategy aiming at enhancing the pre-existing anti-CCL2 antibodies might be beneficial as the sera concentration of these antibodies might not be elevated enough to completely suppress monocyte infiltration and tumor cell migration. Here, CCL2 is linked to neoplasm.